Multiple Antigen

Automated 5-plex fluorescent immunohistochemistry with tyramide signal amplification using antibodies from the same species
Wenjun Zhang, Antony Hubbard, Tobin Jones, Srabani Bhaumik, Adriana Racolta, Mark Lefever, Karl Garsha, Nicholas Cummins, Franklin Ventura, Lei Tang

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P111; DOI: 10.1186/2051-1426-3-S2-P111
A randomized, double-blind, placebo-controlled, Phase I/II trial of RNActive^®-vaccine cv9104 in patients with metastatic castrate-refractory prostate cancer (mcrpc): first results of the Phase I part
Sven D Koch, Henoch Hong, Susan Feyerabend, Margitta Retz, Hubert Kuebler, Axel Heidenreich, Thomas van Erps, Andreas Schroeder, Birgit Scheel, Valérie Reus, Karl-Josef Kallen, Mariola Fotin-Mleczek, Ulrike Gnad-Vogt, Arnulf Stenzl

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P85; DOI: 10.1186/2051-1426-2-S3-P85
Lm-LLO immunotherapies targeting multiple antigens and their impact on different mechanisms in the tumor microenvironment
Anu Wallecha, Poonam Molli

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P63; DOI: 10.1186/2051-1426-2-S3-P63
A phase I/IIa study of the mRNA based cancer vaccine CV9103 prepared with the RNActive technology results in distinctly longer survival than predicted by the Halabi Nomogram which correlates with the induction of antigen-specific immune responses
Karl-Josef Kallen, Ulrike Gnad-Vogt, Birgit Scheel, Gerd Rippin, Arnulf Stenzl

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P219; DOI: 10.1186/2051-1426-1-S1-P219

Log in using your username and password

Main menu

Log in using your username and password

You are here

Multiple Antigen